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Pharmacological screeningAbstract In present study o-phenylenediamine and phenoxyacetic acid were used as starting mate-
rial through series of steps 2-[2-(phenoxymethyl)-1H-benzimidazol-1-yl]acetohydrazide 5 was
obtained. Various derivatives of 2-[2-(phenoxymethyl)-1H-benzimidazol-1-yl]-N0-[(Z)-phenylme-
thylidene]acetohydrazide and some compounds containing oxadiazole bearing benzimidazole were
synthesized by using various aromatic aldehyde, cyanogens bromide and carbon disulﬁde/potas-
sium hydroxide. These were elucidated by IR, NMR and elemental analysis and their in vivo anti-
convulsant screening was performed using MES and scPTZ. Two compounds 7g and j were found
to be potent in both the screens and their protective index was found to be better than standard
drugs used.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
All the heterocyclic compounds are of great interest in phar-
maceutical chemistry. Out of these heterocyclic compounds
the benzfused heterocyclic compound, i.e. benzimidazole and
its derivatives have wide variety of biological activities like
antimicrobial activity (Kumar et al., 2006; Afaf et al., 2000;kazimierczuk et al., 2002; Shetgiri and Kokitkar, 2001; Ansari
and Lal, 2009), antiinﬂammatory-analgesic (Khan and
Nandan, 1997; Evans et al., 1996; Taha, 2005), anticancer
(Demirayak et al., 2002), CNS depressant (Sharma et al.,
1999), androgen receptor antagonist (Raymond et al., 2007),
antitubercular (Kaghthara et al., 1999; Foks et al., 2006) and
anticonvulsant (Chmirri et al., 1989, 2002; Vostrova et al.,
1986; Singh, 1969, 1970). In addition the benzimidazole have
played a very important role in the development of theory in
heterocyclic chemistry and also extensively in organic synthe-
sis. Benzimidazole nucleus is present in vitamin-B12 (Merck in-
dex 2001), albendazole, mebendzole and thiabendazole. In this
present study some novel derivatives of schiff bases containing
benzimidazole nucleus and oxadiazole bearing benzimidazole
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anticonvulsant activity have been established.2. Experimental
2.1. Instrumentation
The entire chemical reagents which are used in the study were
procured locally. The completion of reaction is monitored thin
layer chromatography (TLC) using toluene:ethyl acetate:for-
mic acid (5:4:1) and benzene:acetone (9:1) as solvent system.
The product is puriﬁed by recrystallisation and purity of the
compounds was checked by thin layer chromatography
(TLC) using silica gel G plates (Merck). The spots were devel-
oped in iodine chamber and viewed under UV lamp. Melting
points were determined in an open capillary using melting
point apparatus and are uncorrected. The proton magnetic res-
onance (1H NMR) spectra were recorded on a Brucker
300 MHz instrument in DMSO-d6 using tetramethylsilane as
internal standard. The infrared spectra of compounds were re-
corded in KBr on a Bio Rad FTIR Spectrophotometer.
2.1.1. Procedure for the synthesis of 2-(phenoxymethyl)-1H-
benzimidazole (3)
A mixture of o-phenylenediamine 1 (0.05 mol; 5.40 g) and phe-
noxyacetic acid 2 (0.05 mol; 7.60 g) in round bottom ﬂask and
reﬂuxed in 4 N HCl for 3 h on water bath. After completion of
the reaction, the solution was poured onto crushed ice, NaOH
solution was added drop wise to neutralize and the resulting
solid was ﬁltered, washed with cold water, dried and recrystal-
lized. Yield 80%; m.p. 160–164 C, IR (KBr) cm1: 1240
(CAO), 1540 (C‚N), 3450 (NAH): 1H NMR (DMSO-d6) d
ppm: 5.29 (s, 2H, OCH2), 6.85–7.70 (m, 9H, aromatic), 12.31
(s, 1H, NH). Anal. Cacd for C14H12N2O: C, 74.98; H, 5.39;
N, 12.49; O, 7.13. Found: C, 75.0; H, 5.35; N, 12.45; O, 7.10%.
2.1.2. Procedure for the synthesis of ethyl [2-(phenoxymethyl)-
1H-benzimidazol-1-yl] acetate (4)
To a mixture of 2-(phenoxymethyl)-1H-benzimidazole 3
(0.05 mol; 11.2 g) in dry acetone (100 ml), and potassium car-
bonate (4 g), ethylchloro acetate was added drop wise at room
temperature for a period of 20–30 min. The reaction mixture
was stirred at room temperature for 10–15 h. The solid thus
obtained was ﬁltered off and ﬁltrate was concentrated underreduced pressure. Yield 70%; m.p. 88–92 C, IR (KBr) cm1:
1240 (CAO), 1540 (C‚N), 1645 (C‚O): 1H NMR (DMSO-d6) d ppm: 5.29 (s, 2H, OCH2), 6.70–7.83 (m, 9H, aromatic),
4.17 (m, 2H, CH2), 1.65 (m, 3H, CH3). Anal. Cacd for
C18H18N2O3: C, 69.66; H, 5.85; N, 9.03; O, 15.47. Found: C,
69.65; H, 5.82; N, 9.01; O, 15.42%.
2.1.3. Procedure for the synthesis of 2-[2-(phenoxymethyl)-1H-
benzimidazol-1-yl]aceto hydrazide (5)
To a mixture of ethyl [2-(phenoxymethyl)-1H-benzimidazol-1-
yl]acetate 4 (0.01 mol; 3.10 g) and hydrazine hydrate 98%
(0.01 mol; 0.49 ml) in alcohol was added and the reaction mix-
ture was reﬂuxed for 4 h. the reaction mixture was cooled and
the solid so obtained was ﬁltered, washed with cold water and
recrystallized from ethanol. Yield 80%; m.p. 178–180 C, IR
(KBr) cm1: 1030 (NAN), 1242 (CAO), 1600 (C‚N), 1656
(C‚O), 3034 (CHAAr), 3287 (NAH); 1H NMR (DMSO-d6)
d ppm: 2.52 (s, 1H, NH2), 4.90 (s, 2H, CH2), 5.48 (s, 2H,
OCH2), 6.92–7.69 (m, 9H, aroamtic), 9.43 (s, 1H, CONH).
Anal. Cacd for C16H16N4O2: C, 64.85; H, 5.44; N, 18.91; O,
10.80. Found: C, 64.86; H, 5.42; N, 18.89; O, 10.77%.
2.1.3.1. Procedure for the synthesis of 5-{[2-(phenoxymethyl)-
1H-benzimidazol-1-yl]methyl}-1,3,4-oxadiazol-2-amine (6). A
methanolic solution of 2-[2-(phenoxymethyl)-1H-ben-
zimidazol-1-yl]acetohydrazide 5 (0.0016 mol; 0.4938 g) and
cyanogen bromide (0.03 mol; 3.15 g) was reﬂuxed approxi-
mately for 5 h. After completion of the reaction, the reaction
mixture was cooled at room temperature and poured onto
crushed ice. On basiﬁcation with sodium bicarbonate (5%), a
solid mass so separated was washed with water and recrystal-
lized from ethanol. Yield 75%; m.p. 80–84 C, IR (KBr) cm1:
1022 (NAN), 1240 (CAO), 1600 (C‚N), 3063 (CHAAr), 3144
(NAH). 1H NMR (DMSO-d6) d ppm: 3.63 (s 2H, NH2), 5.29
(s, 2H, CH2), 5.39 (s, 2H, OCH2), 6.94–7.68 (m, 7H, aromatic).
Anal. Cacd for C17H15N5O2: C, 63.54; H, 4.71; N, 21.79; O,
9.96. Found: C, 63.51; H, 4.67; N, 22.79; O, 9.97%.
2.1.4. General procedure for the Synthesis of 2-[2-(phenoxy-
methyl)-1H-benzimidazol-1-yl]-N’-[substituted phenyl
methylidene]acetohydrazide (7a–j)
A mixture of 2-[2-(phenoxymethyl)-1H-benzimidazol-1-
yl]acetohydrazide (5) (0.0025 mol; 0.738 g) and benzaldehyde
S344 M. Shaharyar et al.and its derivative (0.0025 mol) in dimethyl formamide (10 ml)
was reﬂuxed for 5 h. After completion of the reaction, the reac-
tion mixture was concentrated, cooled and poured in ice cold
water, the precipitate so formed was ﬁltered, dried and recrys-
tallized to give the desired compound.
2.1.4.1. 2-[2-(Phenoxymethyl)-1H-benzimidazol-1-yl]-N’-
[(Z)-phenylmethylidene]acetohydrazide (7a). Yield 70%
(Methanol); m.p. 184–188 C. IR (KBr) cm1: 1083 (NAN),
1237 (CAO), 1731 (C‚N), 3107 (CHAAr). 1H NMR
(DMSO-d6) d ppm: 5.39 (s, 2H, CH2), 5.61 (s, 2H, OCH2),
6.91–7.72 (m, 13H, aromatic), 8.21 (s, 1H, CH), 11.79 (s, 1H,
CONH). Anal. Cacd C23H20N4O2: C, 71.86; H, 5.24; N,
14.57; O, 8.32. Found: C, 71.85; H, 5.20; N, 14.55; O, 8.33%.
2.1.4.2. N0-[(Z)-(2-chlorophenyl)methylidene]-2-[2-(phenoxy-
methyl)-1H-benzimidazol-1-yl]acetohydrazide (7b). Yield 65%
(Methanol); m.p. 174–176 C. IR (KBr) cm1: 1081 (NAN),
1242 (CAO), 1731 (C‚N), 3115 (CHAAr), 712 (2-Cl). 1H
NMR (DMSO-d6) d ppm: 4.98 (s, 2H, CH2), 5.31 (s, 2H,
OCH2), 6.83–7.67 (m, 13H, aromatic), 8.01 (s, 1H, CH),
11.09 (s, 1H, CONH). Anal. Cacd for C23H19ClN4O2: C,
65.95; H, 4.57; N, 13.38; O, 7.64. Found: C, 65.92; H, 4.57;
N, 13.28; O, 7.59%.
2.1.4.3. N0-[(Z)-(4-chlorophenyl)methylidene]-2-[2-(phenoxy-
methyl)-1H-benzimidazol-1-yl]acetohydrazide (7c). Yield 72%
(Methanol); m.p. 220–224 C. IR (KBr) cm1: 742 (CACl),
1243 (CAO), 1599 (N‚C), 1684 (C‚O), 3056 (CHAAr),
3278 (NAH). 1H NMR (DMSO-d6) d ppm: 5.38 (s, 2H,
CH2), 5.61 (s, 2H, OCH2), 6.91–7.77 (m, 13H, aromatic),
8.02 (s, 1H, CH); 11.84 (s, 1H, CONH). Anal. Cacd for
C23H19ClN4O2: C, 65.95; H, 4.57; N, 13.38; O, 7.64. Found:
C, 65.90; H, 4.57; N, 13.31; O, 7.65%.
2.1.4.4. N0-[(Z)-(4-methoxyphenyl)methylidene]-2-[2-(phen-
oxymethyl)-1H-benzimidazol-1-yl]acetohydrazide (7d). Yield
70% (Methanol); m.p. 288–192 C. IR (KBr) cm1: 1257
(CAO), 1608 (N‚C), 1680 (C‚O), 3071 (CHAAr), 3203Table 1 Anticonvulsant activity and minimal motor impairment da
S. No. Compounds Intraperitoneal injection in mi
MES screen
0.5 h 4 h
1 6 – 100
2 7a 300 –
3 7b 100 300
4 7c 100 300
5 7d – 300
6 7e – 300
7 7f – 100
8 7g 30 100
9 7h 100 300
10 7i – 100
11 7j 30 30
12 8 100 300
13 Phenytoin 30 30
14 Ethosuximide – –
a Number of animals used = 6; solvent used – polyethylene glycol; dose
dose whereby bioactivity was demonstrated in half or more of the mic
administered. Statistical analyses were performed by one way ANOVA t(NAH). 1H NMR (DMSO-d6) d ppm: 3.80 (s, 3H, OCH3),
5.38 (s, 2H, CH2), 5.59 (s, 2H, OCH2), 6.89–7.59 (m, 13H, aro-
matic), 7.98 (s, 1H, CH), 11.66 (s, 1H, CONH). Anal. Cacd for
C24H22N4O3: C 69.55; H, 5.35; N, 13.52; O,11.58. Found: C
69.58; H, 5.33; N, 13.49; O,11.60%.
2.1.4.5. N0-[(Z)-(3-methoxyphenyl)methylidene]-2-[2-(phen-
oxymethyl)-1H-benzimidazol-1-yl]acetohydrazide (7e). Yield
63% (Methanol); m.p. 188–190 C. IR (KBr) cm1: 1251
(CAO), 1613 (N‚C), 1665 (C‚O), 3098 (CHAAr), 3213
(NAH). 1H NMR (DMSO-d6) d ppm: 3.69 (s, 3H, OCH3),
4.59 (s, 2H, CH2), 5.23 (s, 2H, OCH2), 6.71–7.70 (m,13H, aro-
matic), 8.01 (s, 1H, CH), 9.66 (s, 1H, CONH). Anal. Cacd for
C24H22N4O3: C, 69.55; H, 5.35; N, 13.52; O, 11.58. Found: C,
69.54; H, 5.33; N, 13.49; O, 11.60%.
2.1.4.6. N0-[(Z)-(3,4-dimethoxyphenyl)methylidene]-2-[2-
(phenoxymethyl)-1H-benzimida zol-1-yl]acetohydrazide (7f).
Yield 79% (Methanol); m.p. 98–100 C. IR (KBr) cm1:
1270 (CAO), 1599 (N‚C), 1692 (C‚O), 3128 (CHAAr),
3472 (NAH). 1H NMR (DMSO-d6) d ppm: 3.80 (s, 3H,
OCH3), 5.39 (s, 2H, CH2), 5.61 (s, 2H, OCH2), 6.92–7.68 (m
12H, aromatic), 7.95 (s, 1H, CH), 11.69 (s, 1H, CONH). Anal.
Cacd for C24H22N4O3: C, 67.55; H, 5.44; N, 12.60; O, 14.40.
Found C, 67.57; H, 5.39; N, 12.65; O, 14.38%.
2.1.4.7. N0-[(Z)-(4-ﬂuorophenyl)methylidene]-2-[2-(phenoxy-
methyl)-1H-benzimidazol-1-yl]acetohydrazide (7g). Yield 67%
(Methanol); m.p. 156–158 C. IR (KBr) cm1: 1078 (NAN),
1225 (CAO), 1746 (C‚N), 2982 (CHAAr), 715 (CAF). 1H
NMR (DMSO-d6) d ppm: 5.19 (s, 2H, CH2), 5.51 (s, 2H,
OCH2), 6.89–7.73 (m, 12H, aromatic), 8.15 (s, 1H, CH),
10.09 (s, 1H, CONH). Anal. Cacd for C23H19FN4O2: C,
68.65; H, 4.76; F, 4.72; N, 13.92; O, 7.95. Found: C, 68.67;
H, 4.69; F, 4.75; N, 13.90; O, 7.96%.
2.1.4.8. N0-[(Z)-(4-aminophenyl)methylidene]-2-[2-(phenoxy-
methyl)-1H-benzimidazol-1-yl]acetohydrazide (7h). Yield 65%
(Methanol); m.p. 184–186 C. IR (KBr) cm1: 1072 (NAN),ta of the compounds (6, 7a–j, 8).
cea
scPTZ screen Neurotoxicity screen
0.5 h 4 h 0.5 h 4 h
– – – 100
– 100 – –
100 300 300 –
– 300 – 300
– 300 100 –
– – – 100
– 300 300 –
– 100 100 300
– 100 – 100
– 100 – 300
– 100 100 –
– 100 – –
– – 100 100
100 300 – –
– 30, 100, 300 mg/kg i.p. The ﬁgures in the table indicate the minimum
e. The animals were examined at 0.5 and 4 h after injections were
echniques followed by Dunnet’s test.
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d6) d ppm: 5.17 (s, 2H, CH2), 5.56 (s, 2H, OCH2), 6.79–7.77
(m, 12H, aromatic), 8.15 (s, 1H, CH), 10.72 (s, 1H, CONH),
4.01 (s, 2H, aromatic CANH). Anal. Cacd for C23H21N5O2:
C, 69.16; H, 5.30; N, 17.53; O, 8.01. Found: C, 69.20; H,
5.33; N, 17.54; O, 8.03%.
2.1.4.9. N0-[(Z)-(4,4-dimethylaminophenyl)methylidene]-2-[2-
(phenoxymethyl)-1H-benz imidazol-1-yl]acetohydrazide (7i).
Yield 64% (Methanol); m.p. 144–146 C. IR (KBr) cm1:
1067 (NAN), 1225 (CAO), 1750 (C‚N), 2979 (CHAAr). 1HSchemeNMR (DMSO-d6) d ppm: 5.24 (s, 2H, CH2), 5.62 (s, 2H,
OCH2), 6.59–7.78 (m, 12H, aromatic), 8.12 (s, 1H, CH), 9.02
(s, 1H, CONH), 2.97 (s, 6H, (NCH3)2). Anal. Cacd for
C25H25N5O2 C, 70.24; H, 5.89; N, 16.38; O, 7.49. Found: C,
70.21; H, 5.90; N, 16.35; O, 7.51%.
2.1.4.10. N0-[(Z)-(4-nitrophenyl)methylidene]-2-[2-(phenoxy-
methyl)-1H-benzimidazol-1-yl]acetohydrazide (7j). Yield 69%
(Methanol); m.p. 150–152 C. IR (KBr) cm1: 1065 (NAN),
1215 (CAO), 1753 (C‚N), 2979 (CHAAr). 1H NMR
(DMSO-d6) d ppm: 5.20 (s, 2H, CH2), 5.59 (s, 2H, OCH2),1




MES scPTZ MES scPTZ
7g 12.4 (9.0–15.9) 402.6 (277.4–526.3) 502.1 (304.4–694.2) 40.5 1.2
7j 22.1 (13.7–31.0) 432.6 (307.4–556.3) 546.5 (348.8–738.6) 24.7 <0.2
Number of animals used = 10; solvent used – polyethylene glycol PI protective index = TD50/ED50.
a Dose in milligrams per kilogram body weight.
b Minimal toxicity which was determined by the rotorod test 30 min after the test drug was administered.
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CONH). Anal. Cacd for C23H19N4No2O2. C, 30.64; H, 2.12;
N, 6.21; O, 3.55. Found: C, 30.60; H, 2.10; N, 6.23; O, 3.57%.
2.1.5. Synyhesis of 5-{[2-(phenoxymethyl)-1H-benzimidazol-1-
yl]methyl}-1,3,4-oxadiazole-2-thiol (8)
To an ethanolic solution of 2-[2-(phenoxymethyl)-1H-ben-
zimidazol-1-yl]aceto hydrazide (0.0025 mol; 0.7388 g) and car-
bon disulﬁde (0.005 mol; 0.38 ml), potassium hydroxide
solution (30%; 5 ml) was added. The reaction mixture was re-
ﬂuxed on water bath for 4 h. After completion of the reaction,
the reaction mixture was cooled at room temperature and
poured onto crushed ice, acidiﬁed with dilute hydrochloric
acid, a solid mass so separated was washed with water and
crystallized from methanol.
Yield 64% (Methanol); m.p. 192–194 C. IR (KBr) cm1:
1031 (NAN), 1253 (CAO), 1593 (C‚N), 3071 (CHAAr),
2368 (SH). 1H NMR (DMSO-d6) d ppm: 3.39 (s 1H, SH),
5.44 (s, 2H, CH2), 5.81 (s, 2H, OCH2), 6.94–7.70 (m, 9H, aro-
matic). Anal. Cacd for C17H14N4O2S C, 60.34; H, 4.17; N,
16.56; O, 9.46; S, 9.48. Found: C, 60.33; H, 4.19; N, 16.60;
O, 9.44; S, 9.49%.
3. Results and discussion
3.1. Chemistry
2-(Phenoxymethyl)-1H-benzimidazole 3 was prepared by
reﬂuxing with o-phenylenediamine 1 and phenoxyacetic acid
2 in presence of 4NHCl. The compound 3 on reacting with eth-
ylchloroacetate in presence of potassium carbonate in dry ace-
tone gave ethyl [2-(phenoxymethyl)-1H-benzimidazol-1-
yl]acetate 4 which on treatment with hydrazine hydrate results
in 2-[2-(phenoxymethyl)-1H-benzimidazol-1-yl]acetohydrazide
5. The compound 5 gave 5-{[2-(phenoxymethyl)-1H-ben-
zimidazol-1-yl]methyl}-1,3,4-oxadiazol-2-amine 6, 2-[2-(phen-
oxymethyl)-1H-benzimidazol-1-yl]-N0-[substituted phenyl
methylidene]acetohydrazide (7a–j) and 5-{[2-(phenoxy-
methyl)-1H-benzimidazol-1-yl]methyl}-1,3,4-oxadiazole-2-
thiol 8 with cyanogen bromide and carbon disulﬁde/potassium
hydroxide.
3.2. Anticonvulsant activities
The compounds synthesized from 2-[2-(phenoxymethyl)-1H-
benzimidazol-1-yl]acetohydrazide 5 were screened for their
anticonvulsant activity through the MES and PTZ test. The re-
sults of the above given test were compared with the standard
drugs (phenytoin and ethosuximide) as mentioned in the Table1. Minimal motor impairment was determined by the rotorod
test. The compound 7g and j were found to exhibit most potent
anticonvulsant activity. Thus these were further evaluated for
their anticonvulsant activity (ED50), Neurotoxicity (TD50)
and protective index comparing with their reference standards.
The protective index of the compound 7g and j were found to
be 40.5 24.7, respectively, which were signiﬁcantly higher than
the standard drugs. The much higher TD50 values exhibited by
the compound 7g and j indicated that these cause marked low-
er neurotoxicity than the standard drugs. Structure activity
relationship has also been studied, the compound containing
nitro and ﬂuoro group at para position was found to be most
active in this series. The substitution with electron withdrawing
group played a very important role and it follows the order
NO2 < F< Cl. On the other hand the substitution with elec-
tron releasing group does not have marked effect on the
activity.
4. Conclusion
The present study has identiﬁed the anticonvulsant effect of
compounds derived from 2-[2-(phenoxymethyl)-1H-ben-
zimidazol-1-yl]acetohydrazide. The compound 7g and j has
shown potent anticonvulsant activity and lesser neurotoxicity
as compared with the standard drugs because NO2 and F have
more electron withdrawing capacity than the other substitu-
ents. The protective index of these two compounds was found
to be better than standard drugs. Thus the study revealed that
these compounds have potential anticonvulsant activity and
can be used for further clinical trials (see Scheme 1).
5. Biological methods
5.1. Anticonvulsant screening
5.1.1. Maximal electroshock seizure test (MES test)
The compounds were screened for their anticonvulsant activity
by electroshock seizure method (Stables and Kupferberg,
1995). Supramaximal electroshock of current intensity of
50 mA, 60 Hz for 0.2 s duration was applied to mice, with
the doses of test compounds 30, 100, 300 mg/kg (Husain
et al., 2011). The abolition of the hind limb tonic extensor
spasm was recorded as anticonvulsant activity as shown in Ta-
ble 1.
5.1.2. Pentylenetetrazole-induced seizure test (PTZ test)
The subcutaneous pentylenetetrazole test was performed
according to the known protocol (Clark et al., 1984). This
method utilizes pentylenetetrazole (75 mg/kg) that produces
Synthesis, characterization and pharmacological screening of novel benzimidazole derivatives S347seizures in >95% of animals as 0.5% solution subcutaneously
in the posterior midline. The animal was observed for 30 min;
failure to observe even a threshold seizure (a single episode of
clonic spasms of at least 5 s duration) was deﬁned as protec-
tion as shown in Table 1. To determine anticonvulsant potency
and toxicity, groups of 10 mice were tested with various doses
of the drug until at least three points were established between
the limits of 90% protection or toxicity and 10% protection or
toxicity. The dose of drug required to produce the desired end-
point in 50% of animals (ED50) in each test, the dose eliciting
evidence of minimal neurological toxicity in 50% of animals
(TD50) are shown in Table 2.
5.1.3. Neurotoxicity screening (NT)
The minimal motor impairment was measured in mice by the
rotorod test (Kucukgzuel et al., 2006; Lien et al., 1979). The
mice (20–25 g) were trained to stay on an accelerating rotorod
that rotates at 10 rotations/min. and its diameter was 3.2 cm.
Only those mice were taken for the test which can stay on
the revolving rod for at least 1 min. Trained animals were in-
jected i.p. with the test compounds at doses of 300 mg/kg.
Neurotoxicity was indicated by the inability of the animal to
maintain equilibration on the rod for at least one minute as
shown in Table 1.
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